While the coronavirus-related workload already is taxing the US Food and Drug Administration staff, Peter Marks worries a post-pandemic bolus may add to the workload crunch.
The director of the FDA’s Center for Biologics Evaluation and Research said 11 June during a session at the Biotechnology...